课题基金 / 基金详情

Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor

Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor
开发一流的 O-GlcNAc 转移酶 (OGT) 抑制剂
批准号:
10675397
负责人:
Craig Thomas
金额:
$31.09万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Craig Thomas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Chemical Technology researchers develop small molecule and screening approaches that other scientists can use to pursue innovations in therapeutic development. O-GlcNAc transferase (OGT) is an essential enzyme that catalyzes the attachment of O-GlcNAc residues to nuclear and cytoplasmic proteins including kinases, transcription factors, histones and many other proteins which, in turn, regulate numerous cellular processes. O-GlcNAcylation is still not well understood, and small molecule inhibitors of OGT will be a key tool for the dissecting of this important enzymes function in the cell. Working with the Walker lab (Harvard), we have developed a novel small molecule OGT inhibitor and validated its activity in several different mammalian cell lines without affecting synthesis of cell surface N- or O-linked glycans. We are continuing to optimize this agent and are pursuing numerous collaborations using this probe of OGT biology to delineate its role in multiple cell lines and disease settings.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy
Novel small molecule library development
The development of multikinase inhibitors for the treatment of selected cancers
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor
国内基金
海外基金
Journal of Integrative Plant Biology
  • 批准号:
    31024801
  • 项目类别:
    专项基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2010
  • 负责人:
    贺萍
  • 依托单位: